US · Healthcare · Biotechnology
EPS came in at 18.43 against a street estimate of 13.76 — a beat of 33.9%.
Analysts rate Regeneron Pharmaceuticals Inc a buy (19 buy, 8 hold, 1 sell out of 28) with an average price target of $977.93.
CONFIDENT Regeneron delivered a strong third quarter, with 36% revenue growth, 70% non-GAAP EPS growth, record Dupixent, EYLEA HD and Libtayo sales, and multiple late-stage pipeline catalysts. Q3 FY26 U.S. performance was led by Dupixent, EYLEA HD and Libtayo; Dupixent global sales also grew strongly at constant currency. Analysts focused on Side B differentiation, business development, next-generation inflammation assets and launch preparation. Management emphasized genetic validation, selective dealmaking, longer dosing intervals and leveraging existing commercial capabilities. 2026-10-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.81% |
| Vanguard Capital Management, LLC | 6.41% |
| Dodge & Cox | 4.71% |
| State Street Corp | 4.67% |
| Amvescap Plc. | 3.81% |
| JPMorgan Chase & Co | 3.65% |
| Vanguard Portfolio Management, LLC | 3.07% |
| Franklin Templeton Inc | 2.68% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $5,115.8 million, up from $3,754.3 million in Q3 2025. Nine-month revenue was $13,011.9 million ver | 2026-10-30 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue rose 36% year over year to $5.116 billion, from $3.754 billion. • GAAP net income increased 33% to $1.949 billion | 2026-10-30 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Regeneron and Sanofi signed the Sixth Amendment to their collaboration agreement on October 1, 2026. • Sanofi will pay Regeneron | 2026-10-06 |
| Board / officer change · Q3 2026 HEADLINE NUMBERS • Regeneron granted one-time, performance-based awards to CEO Leonard S. Schleifer and CSO George D. Yancopoulos on September 24, 20 | 2026-09-30 |
| Quarterly report · Q2 2026 REGENERON PHARMACEUTICALS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net income Q2 2026: $1,296.9 million | Q2 2025: $1,391.6 million (down 6.8 | 2026-07-30 |
| Results announced · Q3 2026 REGENERON PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 total revenues: $4.3 billion, up 17% versus Q2 2025 ($3.7 billion) • | 2026-07-30 |
| Results announced · Q3 2026 REGENERON PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Acquired in-process research and development (IPR&D) charge of approximately $ | 2026-07-06 |
| Shareholder vote results · Q2 2026 REGENERON PHARMACEUTICALS, INC. — 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 12, 2026 • Company trades on NASDAQ under tick | 2026-06-17 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.94 / share ex-date Nov 20, 2026 · pay Dec 3, 2026 | 2026-11-20 |
| Dividend | $0.94 / share ex-date Aug 18, 2026 · pay Aug 31, 2026 | 2026-08-18 |
| Dividend | $0.94 / share ex-date May 20, 2026 · pay Jun 4, 2026 | 2026-05-20 |
| Dividend | $0.94 / share ex-date Feb 20, 2026 · pay Mar 5, 2026 | 2026-02-20 |
| Dividend | $0.88 / share ex-date Nov 20, 2025 · pay Dec 5, 2025 | 2025-11-20 |
| Announcement | Date |
|---|---|
| Sanofi partnership adds four antibodies with $1 billion upfront and up to $7 billion milestones Regeneron and Sanofi expanded their long-running partnership to jointly develop and commercialize four new long-acting antibodies invented by Regeneron, targeting IL-13, IL-4, IL-4Rα, and IL | 2026-10-06 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Regeneron Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.